pharmapoint ulcerative colitis global drug forecast and market analysis to 2022 n.
Skip this Video
Loading SlideShow in 5 Seconds..
JSB Market Research - PharmaPoint: Ulcerative Colitis - Glob PowerPoint Presentation
Download Presentation
JSB Market Research - PharmaPoint: Ulcerative Colitis - Glob

JSB Market Research - PharmaPoint: Ulcerative Colitis - Glob

127 Vues Download Presentation
Télécharger la présentation

JSB Market Research - PharmaPoint: Ulcerative Colitis - Glob

- - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

  1. PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022

  2. Summary • During the forecast period from 20122022, the growth of the UC market will be driven largely by the entry of Johnson & Johnsons (J&Js) Simponi and Takedas Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada. Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and Humira are set to expire in the US in 2018 and 2016, respectively. Overall, major barriers to the growth of the UC market include: Remicade and Humira losing patent protection in the mid-forecast Austerity measures favoring generic prescribing Biosimilars are predicted to face low uptake due to the lack of regulatory guidelines in some markets, such as the US 

  3. Scope • Overview of UC, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current treatment options. • Annualized UC therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2012 to 2022. • Key topics covered include strategic competitor assessment, market characterization, unmet needs, and implications for the UC therapeutics markets. • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late stage pipeline drugs. • Analysis of the current and future market competition in the global UC therapeutics markets. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

  4. Market Model Features • An interactive excel forecast model based on primary research interviews and surveys with KOLs and high-prescribing physicians is included in this report*. This patient based model provides diagnosis rates, patient segmentation, treatment rates, annual costs of therapy , and indication-specific drug sales for the 10 year forecast period. The forecast model is robust, fully transparent, and easy to navigate. Moreover, our models support data presented in the reports and the complete methodology is outlined in the report and the model.*Model only available with site and global license purchases. • Check Full Report on :

  5. PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis

  6. Related Market Research Report • Allergy Drugs Markets in China • Arthritis Treatment Drugs Markets in China • Asthma Treatment Drugs Markets in China • Diabetes Drugs Markets in China • Pain and Fever Relief Drugs Markets in China • Cough Drugs Markets in China

  7. About JSB Market Research • is an online repository of an extensive collection of market research reports available online. This online portal contains high-quality reports with well-researched and high-quality content on a wide range of industries. These market research reports help us give a detailed insight into new opportunities in the industry, prevailing market trends, competitor analysis and future prospects. • JSB’s reports are developed by the domain experts and publishers under a closely observed surveillance of industry specialists. Therefore, the researched data is well researched, well- organized and matching up to the best standards in the industry. Also JSB’s database consists of detailed insights of the leading players in the global market, products and trends.

  8. Contact Us Support & General Inquiries Mail - 998 729 5242 Billing Support Mail 22 412 366 50 Website